SEC Form 4 · accession 0001209191-19-006609
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jessica Oien
Officer — General Counsel & Secretary
Period of report
Jan 31, 2019
Accepted (ET)
Feb 1, 2019 · 7:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2019 | A | 6,000 | $0.00 | A | 6,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Jan 31, 2019 | M | 14,000 | A | — | Jan 1, 2022 | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F11/3rd of the total number of shares subject to the restricted stock unit shall vest on each January 1 of 2020, 2021 and 2022.
- F2Restricted stock units convert into common stock on a one-for-one basis.
- F3The shares shall vest upon the achievement of various clinical and corporate milestones.